Direct answer. Aortic stenosis is narrowing of the aortic valve, which opens between the left ventricle and the aorta. The heart must push blood through a restricted opening. Some people have no recognized symptoms, while severe disease can cause important exertional symptoms or heart failure. Echocardiography and an integrated clinical assessment establish severity and the appropriate care pathway. Confidence is high in these distinctions; device comparisons in professional guidance are not treated as independently financially cleared efficacy evidence. NHLBI valve anatomy and types, March2022.
- Narrowing differs from leakage; the same valve can have both problems.
- Exertional breathlessness, chest discomfort or fainting need assessment, especially when the valve is known to be narrowed.
- A low measured pressure gradient does not automatically exclude severe stenosis when forward flow is reduced.
- Medicines can treat accompanying conditions but are not presented here as a way to reopen a calcified valve.
- Surgical and catheter replacement require a valve-team decision based on anatomy, life expectancy, other disease and patient preferences.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| What is obstructed? | Public valve anatomy | The outlet from the left ventricle through the aortic valve. High confidence. |
| Can one echo number settle severity? | 2025 integrative imaging guidance | No. Measurements, flow, function and clinical findings are reconciled. |
| Is every asymptomatic case observed indefinitely? | Attributed current specialist guidance | No. Severity and selected risk findings can affect intervention timing. |
| Which replacement is best? | Care context and funding audit | Individual choice; no independent universal device ranking established. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
The aortic valve normally opens to let blood leave the left ventricle and closes to limit backward flow. Stenosis describes an opening that is too restricted. Regurgitation describes leakage back through it; both can coexist. A murmur is a sound heard on examination and can lead to further investigation, but its presence or loudness alone does not establish the severity of obstruction. NHLBI valve anatomy and types, March2022.
Narrowing can develop as valve leaflets become calcified and less mobile. A congenital bicuspid valve has two main leaflets rather than the usual three and can develop important disease earlier. Rheumatic disease and other contributors also occur. The cause and associated aortic or other valve abnormalities matter because an older adult with calcific disease and a child with congenital obstruction need different pathways. NHLBI valve disease causes, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Breathlessness, reduced capacity, chest discomfort and dizziness or fainting can occur. Someone may gradually avoid activity and therefore describe themselves as symptom-free despite a meaningful change in capacity. Conversely, similar symptoms can arise from coronary, lung or other disease. The assessment should establish both the valve findings and the likely explanation for symptoms. NHLBI valve disease symptoms, March2022.
How it works
A narrowed outlet increases the work required to move blood forward. The ventricle can change its structure in response, and later develop impaired relaxation or contraction. Pressure load, effective forward flow and additional cardiac disease are related but separate findings; a normal-looking ejection fraction alone does not describe all of them. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Echo measures valve motion and flow and assesses the ventricle and other valves. In the current specialist framework, a pressure gradient is interpreted alongside valve area, blood-flow state and function. Reduced flow can produce a low gradient despite important obstruction. When findings disagree, clinicians may check technical measurements and use selected CT or supervised stress imaging rather than picking whichever number seems reassuring. No numerical home interpretation rule is offered here. NHLBI valve disease diagnosis, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Coexisting hypertension, coronary disease, amyloidosis or another muscle disorder can affect the presentation and treatment. Treating one problem does not prove that the narrowed valve is unimportant, and detecting stenosis does not establish that every symptom is caused by it. A useful report explains the integrated conclusion and remaining uncertainty. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
The evidence-based treatments
Care can involve planned surveillance for less severe disease or an intervention assessment for important stenosis. The 2025 ESC/EACTS guideline uses symptoms, established severity, ventricular findings and selected risk features to guide timing. Some people without reported symptoms may still merit an intervention discussion. This is attributed specialist care context, with the financial limitations below, rather than a blanket instruction to operate or wait. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Blood-pressure or heart-failure treatment can manage associated problems. The guideline does not identify a medicine that changes the natural history of aortic stenosis; symptom improvement from accompanying treatment should not substitute for an appropriate valve assessment. A statin may have a separate cholesterol indication, but that should not be recast as proven reversal of valve narrowing. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Replacement can be performed surgically or by transcatheter aortic valve implantation/replacement, called TAVI or TAVR. Selection considers anatomy, vascular access, associated coronary or aortic surgery, future procedures, expected longevity, durability and preference. Trial populations and implant designs differ, so “less invasive” alone cannot settle which choice suits a particular person. The guide supplies no manufacturer ranking or sponsored comparative outcome estimate. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Mechanical prostheses require a long-term anticoagulation plan. Tissue prostheses and catheter valves have their own antithrombotic and follow-up requirements, and other conditions can create a separate need for anticoagulation. It is therefore misleading to promise that everyone with a tissue valve needs no blood thinner. The team should explain the selected device, monitoring and likely future management before consent. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Supplement and lifestyle evidence
Discuss the safe intensity of activity before starting or increasing an exercise programme. Severe or symptomatic disease requires a specific plan rather than advice to push through breathlessness. Smoking cessation, appropriate nutrition and management of other cardiovascular risks support general care, but do not demonstrate that the narrowing has reversed. NHLBI valve care background, March2022.
No supplement is established here as a treatment for aortic stenosis. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful surveillance records the current valve grade, symptoms and capacity, ventricular response and the reason for the next review. It also gives a contact route for changes between scans. A strategy of clinical observation is an active follow-up plan, not an instruction to ignore new symptoms; after intervention, prosthesis function and other cardiac problems still need assessment. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
Severe breathing difficulty, collapse or new concerning chest pain needs emergency help. New exertional fainting, significant chest symptoms or rapidly worsening breathlessness should not be postponed until a routine surveillance appointment. An unresponsive person who is not breathing normally needs emergency dispatch instructions and CPR/AED help. NHS current national heart valve disease education.
Valve intervention can cause bleeding, stroke, clot-related events, kidney or cardiac injury, infection or residual leakage. Some people need a pacemaker or later reintervention. Medicines can alter pressure, kidney function or electrolytes, and anticoagulants increase bleeding risk. The purpose, individual risk and monitoring for the chosen strategy should be discussed together. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Important interactions
Blood-pressure treatment, diuretics, rate medicines and anticoagulants require an integrated review, particularly when pressure or kidney function is changing. Inform the team about non-prescription products before a procedure. Do not borrow a vasodilator or change fluid, salt or blood-thinner treatment on the assumption that all chest symptoms have the same cause. NHLBI valve care background, March2022.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
Ask which findings establish severity, whether the measurements agree, how symptoms and ventricular function fit, and whether the aorta or other valves also need evaluation. Echocardiography is central; CT, MRI, coronary investigation or supervised exercise assessment is selected for a particular question. A home exertion challenge is not a safe way to settle symptoms or intervention timing. NHLBI valve disease diagnosis, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Pregnancy planning, a previous valve intervention, kidney disease and anticoagulant use deserve specific review. The current status of the valve matters more than an old diagnostic label. Children with congenital disease need an age-appropriate specialist pathway rather than an adult intervention rule. NHLBI valve disease and pregnancy, March2022.
Clinician-led use and follow-up
Ask for the surveillance interval, the findings that might change the plan, and instructions for new symptoms. After replacement, clarify antithrombotic treatment, device follow-up and dental or procedural precautions. Pregnancy plans should be discussed before medication changes or conception when possible; no personal drug dose or self-selected scan threshold is provided. NHLBI valve disease and pregnancy, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Laboratory work on valve calcification, connective tissue or blood-flow mechanics can help investigate a mechanism. It cannot determine a safe human supplement dose, establish that a calcified valve will reopen, or select an implant for an individual. An animal or cell finding does not replace a clinical assessment of anatomy, severity and complications. No animal or in-vitro result contributes to this guide’s independent clinical verdict.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 16 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Financial interests include echocardiography and advanced imaging, valve implants, surgical and catheter services, medicines and marketed supplements. Valve-device manufacturers and professional societies can have relevant financial relationships even when the document itself reports no direct industry-development funding. Those routes and unresolved author/trial chains are shown below; no manufacturer or materially conflicted outcome claim establishes this guide’s independent verdict.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI valve anatomy and types, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public anatomy and distinctions between stenosis, regurgitation and prolapse. |
| NHLBI valve disease causes, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public inherited and acquired contributor education. |
| NHLBI valve disease symptoms, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Public symptom education; symptoms do not establish severity. |
| NHLBI valve disease diagnosis, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Clinical investigation background; no self-diagnostic thresholds. |
| NHLBI valve care background, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced. |
| NHS current national heart valve disease education | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: January 2025 national condition and emergency education; broad prolapse wording not reproduced. |
| Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF | The original guideline states document development was financed entirely by ESC and EACTS without healthcare-industry involvement. ESC institutional revenues nevertheless include life-science and medtech partnerships; EACTS discloses industry/charity grants and an Edwards Lifesciences Foundation partnership. That separate route does not prove Edwards funded this guideline. The official 2025 author declaration report returned 403 and was not read. Article allocation, individual author independence and original device/drug trial chains remain unresolved. | France: ESC, Sophia Antipolis. United Kingdom: EACTS, Windsor, registered England and Wales; OUP publisher UK. International writing panel. The unchanged original EJCTS PDF mirror is hosted by MATCVS, Malaysia; it does not change the document author or funding origin. Edwards corporate headquarters Irvine, California, US; specific supplied-device manufacturing origin unresolved. | Tier 2 documented society industry routes, with unresolved author chain; independent efficacy excluded. | C provisional. Original 109-page guideline and August 2026 correction checked. Detailed methodology, specialist review and explicit evidence grades aid attributed clinical use; society commercial routes, inaccessible author declarations and uncleared original-trial finances prevent a clean independent outcome verdict. Role: Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy. |
| NHLBI valve disease and pregnancy, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Pregnancy planning and medication-safety context. |
| NHLBI valve disease definitions, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| ESC funding and revenue model | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| ESC conflict management policy | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| EACTS current industry/charity grant and Edwards Foundation relationship | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS industry sponsorship route | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS registered jurisdiction and Windsor contact | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| Edwards corporate/foundation funding and technology-donation routes | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
| Edwards global headquarters and manufacturing-location disclosure | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
Frequently asked questions
Does no chest pain mean the valve is safe? No. Capacity, breathlessness, fainting, imaging and other findings are assessed together; some people unknowingly reduce activity. NHLBI valve disease symptoms, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Does a low gradient exclude severe disease? Not automatically. Flow and the reliability of the measurements affect interpretation, and selected further testing may resolve disagreement. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Can supplements dissolve valve calcium? This source set establishes no clinically proven, financially screened supplement regimen for reopening a stenotic valve. Laboratory calcification mechanisms are not a human treatment verdict.
Is TAVI always preferable to surgery? No. Anatomy, accompanying disease, longevity, durability and preferences enter a specialist decision; a technique name is not an individual recommendation. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Sources and funding notes
- NHLBI valve anatomy and types, March2022 — Dated public anatomy and distinctions between stenosis, regurgitation and prolapse.
- NHLBI valve disease causes, March2022 — Dated public inherited and acquired contributor education.
- NHLBI valve disease symptoms, March2022 — Public symptom education; symptoms do not establish severity.
- NHLBI valve disease diagnosis, March2022 — Clinical investigation background; no self-diagnostic thresholds.
- NHLBI valve care background, March2022 — Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced.
- NHS current national heart valve disease education — January 2025 national condition and emergency education; broad prolapse wording not reproduced.
- Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF — Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy.
- NHLBI valve disease and pregnancy, March2022 — Pregnancy planning and medication-safety context.
- NHLBI valve disease definitions, March2022 — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- ESC funding and revenue model — Financial provenance only.
- ESC conflict management policy — Financial provenance only.
- EACTS current industry/charity grant and Edwards Foundation relationship — Financial provenance only.
- EACTS industry sponsorship route — Financial provenance only.
- EACTS registered jurisdiction and Windsor contact — Financial provenance only.
- Edwards corporate/foundation funding and technology-donation routes — Financial provenance only.
- Edwards global headquarters and manufacturing-location disclosure — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. The original 109-page 2025 ESC/EACTS valve guideline was read from MATCVS’s unchanged EJCTS/OUP PDF mirror, with its title, authors and DOI verified. The official August 6, 2026 correction was opened separately. The official author-declaration PDF returned 403 and was not read. Actual ESC, EACTS and Edwards financial-route disclosures were checked; separate institutional industry support does not establish direct industry financing of this document. Individual author and original-trial financial chains remain unresolved; clinical recommendations are C-provisional context. Clinical sources concentrate on US and English public education plus European professional guidance. This limits jurisdictional breadth: referral, implant availability and treatment systems vary, and no global access claim is inferred. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.